ArticleCurrent medical science2026
Efficacy and Safety of Jiannao Tongluo Granules in the Treatment of Convalescent Cerebral Infarction: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial.
Article in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveThis study aimed to investigate the efficacy and safety of Jiannao Tongluo (JNTL) granules in patients with convalescent cerebral infarction and to explore the underlying mechanisms.
methodsA randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted from November 2024 to November 2025. A total of 110 eligible patients were randomly assigned at a 1:1 ratio to receive either JNTL granules or placebo control for 12 weeks on the basis of standard secondary prevention and comprehensive rehabilitation. The primary outcome was the variation in the Montreal Cognitive Assessment (MoCA) score. The secondary outcomes included the Vascular Dementia Assessment Scale-Cognitive Subscale (VaDAS-cog), Mini-Mental State Examination (MMSE), Fugl-Meyer Assessment (FMA), modified Barthel index (MBI), and TCM symptom score (SYM), which were measured at baseline and at weeks 4, 12, and 24. Serum inflammatory factors (hs-CRP, IL-6, IL-1β, TNF-α, and SAA) and neurotrophic factors (BDNF and VEGF) were measured at baseline and week 12. The activation of the cerebral cortex was evaluated by functional near-infrared spectroscopy (fNIRS) at baseline and week 12. Safety was monitored throughout the trial.
resultsA total of 97 patients (48 in the JNTL granule group and 49 in the control group) completed the trial, for a dropout rate of 11.8%. Baseline characteristics were well balanced between the groups (all P > 0.05). At 12 and 24 weeks, the JNTL granule group showed more substantial increases in the MoCA, MMSE, FMA, and MBI scores and lower VaDAS-cog and SYM scores than the control group (all P < 0.05). At week 12, compared with the control treatment, JNTL granules treatment significantly reduced serum levels of hs-CRP, IL-6, IL-1β, TNF-α, and SAA, and increased serum BDNF and VEGF levels (all P < 0.05). fNIRS revealed that the JNTL granules significantly enhanced task-evoked HbO activation in the temporal cortex (TC), Broca's area, and premotor and supplementary motor cortex (PreM/SMC) (all P < 0.05). There were no reports of serious adverse events.
conclusionJNTL granules effectively improve cognitive function, motor function, and activities of daily living (ADL) in patients with convalescent cerebral infarction of wind-phlegm obstructing collateral syndrome, with durable efficacy and favorable safety. The mechanisms may involve the suppression of excessive inflammatory responses, the promotion of neuroprotection and angiogenesis, and the enhancement of activation in key cognitive-motor-related cortical regions.
Indexed as
Identifiers
42678478What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.